DOACScore Downloads & RevenueDOACScore · App Store
Not in any tracked top chart right now.
Updated 2 Nov 2026 · rankings refresh through the day
DeveloperPhilip Cumpston
CategoryMedical
Price0.99 EUR
Released
Rating★ 0.0 (0)
Version1.4
Age rating17+
First seen by us
4 Oct 2026
4 Oct 2026Full timeline · 3 events in the last 12 months
- 📈DOACScore dropped out of every chart we trackLast seen 5 Oct
- 🆕DOACScore first spotted by AppInsider#14 in Top Paid · Medical · Italy
- 🆕DOACScore released on the App Store
Collected from the stores by AppInsider since we first spotted the app. Dates are when we saw each change.
Rating
0.0 ★
0 ratings
Measured
DOACScore on the App Store
App details
App ID
6740561711
Publisher
Philip Cumpston
On the store since
Jan 2025
1 year on the store
Minimum OS
iOS 11.0+
iPhone 5s and later
Devices
iPhone · iPad
Universal purchase
Content rating
17+
Languages
1
EN
Size
17 MB
Also listed in
Utilities
Where it ranks now
Every top chart it appears in across 30 countries.
| Country | Charts | Rank |
|---|---|---|
| Not charting right now. | ||
Ratings
App Store, worldwide.
Rating
0.0 ★
0 ratings
Measured
Ratings
0
Measured
About DOACScore
This application is provided for the use of cardiologists and cardiac electrophysiologists, not the general public. If the user is not a cardiologist and wishes to use the app, then they should consult their cardiologist for further advice. The app does not provide any information regarding the dose or usage of direct acting anticoagulants.
The DOAC score represents a significant scientific advance in anticoagulation management that balances the benefit of preventing stroke and systemic embolization with the risk of bleeding in patients with atrial fibrillation.The DOAC score allows the clinician to accurately quantify bleeding risk in patients taking DOACs while also helping identify bleeding risk factors and to correct those that are modifiable such as better controlling blood pressure, removing concomitant unnecessary antiplatelet or NSAID use, and counseling the patient about such factors. The bleeding risk assessment with the DOAC score and its clinical adoption improves patient care, highlight patients in whom risks are reversible, and provides caution when needed.
The DOAC score could also potentially serve as a quantifiable measure with respect to selecting patients who might benefit from left atrial appendage closure and/or catheter ablation.
The % one year bleeding risk is taken from development and validaiton cohorts and should only be considered a rough estimate.
1. Aggarwal R, Ruff CT, Virdone S, Perreault S, Kakkar AK, Palazzolo MG, et al. Development and Validation of the DOAC Score: A Novel Bleeding Risk Prediction Tool for Patients With Atrial Fibrillation on Direct-Acting Oral Anticoagulants. Circulation [Internet]. 2023 Sep 19 [cited 2025 Jan 14];148(12):936–46. Available from: https://www.ahajournals.org/doi/10.1161/CIRCULATIONAHA.123.064556
2. Ezekowitz MD, Kamareddine M. Filling an Important Knowledge Gap: The DOAC Score. Circulation [Internet]. 2023 Sep 19 [cited 2025 Jan 15];148(12):947–9. Available from: https://www.ahajournals.org/doi/10.1161/CIRCULATIONAHA.123.066316
3. Harano Y, Yamamoto M, Shimura T, Okubo M, Koyama Y, Yamaguchi R, et al. Association Between Direct Oral Anticoagulant Score and Bleeding Events in Patients With Atrial Fibrillation Following Transcatheter Aortic Valve Replacement: A Retrospective Multicenter Cohort Study. JAHA [Internet]. 2024 Nov 7 [cited 2024 Nov 15];e036417. Available from: https://www.ahajournals.org/doi/10.1161/JAHA.124.036417
The DOAC score represents a significant scientific advance in anticoagulation management that balances the benefit of preventing stroke and systemic embolization with the risk of bleeding in patients with atrial fibrillation.The DOAC score allows the clinician to accurately quantify bleeding risk in patients taking DOACs while also helping identify bleeding risk factors and to correct those that are modifiable such as better controlling blood pressure, removing concomitant unnecessary antiplatelet or NSAID use, and counseling the patient about such factors. The bleeding risk assessment with the DOAC score and its clinical adoption improves patient care, highlight patients in whom risks are reversible, and provides caution when needed.
The DOAC score could also potentially serve as a quantifiable measure with respect to selecting patients who might benefit from left atrial appendage closure and/or catheter ablation.
The % one year bleeding risk is taken from development and validaiton cohorts and should only be considered a rough estimate.
1. Aggarwal R, Ruff CT, Virdone S, Perreault S, Kakkar AK, Palazzolo MG, et al. Development and Validation of the DOAC Score: A Novel Bleeding Risk Prediction Tool for Patients With Atrial Fibrillation on Direct-Acting Oral Anticoagulants. Circulation [Internet]. 2023 Sep 19 [cited 2025 Jan 14];148(12):936–46. Available from: https://www.ahajournals.org/doi/10.1161/CIRCULATIONAHA.123.064556
2. Ezekowitz MD, Kamareddine M. Filling an Important Knowledge Gap: The DOAC Score. Circulation [Internet]. 2023 Sep 19 [cited 2025 Jan 15];148(12):947–9. Available from: https://www.ahajournals.org/doi/10.1161/CIRCULATIONAHA.123.066316
3. Harano Y, Yamamoto M, Shimura T, Okubo M, Koyama Y, Yamaguchi R, et al. Association Between Direct Oral Anticoagulant Score and Bleeding Events in Patients With Atrial Fibrillation Following Transcatheter Aortic Valve Replacement: A Retrospective Multicenter Cohort Study. JAHA [Internet]. 2024 Nov 7 [cited 2024 Nov 15];e036417. Available from: https://www.ahajournals.org/doi/10.1161/JAHA.124.036417
Latest updates
1.4
